Skip to main content
Clinical Trials/NCT05159817
NCT05159817
Active, not recruiting
Not Applicable

Monocentre, Observational Clinical Study Evaluating the Efficacy and Safety of a Novel Interposition Supraciliary Implant in Glaucoma Surgery

Ciliatech1 site in 1 country19 target enrollmentDecember 15, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glaucoma, Open-Angle
Sponsor
Ciliatech
Enrollment
19
Locations
1
Primary Endpoint
Assess post-op IOP reduction
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.

Detailed Description

19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted. These patients reached 6 months follow-up and the original study had to be interrupted. This observational study prolonges follow-up to 36 months

Registry
clinicaltrials.gov
Start Date
December 15, 2021
End Date
December 31, 2024
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ciliatech
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655

Exclusion Criteria

  • if cannot assist to all future follow-up visits

Outcomes

Primary Outcomes

Assess post-op IOP reduction

Time Frame: 12, 24 and 36 months

Proportion of Eyes With Intraocular Pressure (IOP) Reduction of ≥ 20%

Study Sites (1)

Loading locations...

Similar Trials